Novo Nordisk files multiple lawsuits in the U.S. for trademark infringement and false advertising. Novo Nordisk filed a series of lawsuits across the country last week, accusing a number of companies, including weight loss clinics and medical spas, of infringing its trademark rights and improperly promoting its semaglutide products Ozempic, Wegovy and Rybelsus. The pharmaceutical company filed nine lawsuits, alleging that the defendants abused its trademark rights by marketing semaglutide-based combination weight loss drugs without approval from the U.S. Food and Drug Administration. Nearly half of the cases were filed in Florida, and the company also filed lawsuits in Tennessee, Montana, Colorado, Illinois and Texas.
Founded in 1923, Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd with production facilities in nine countries and affiliates or offices in five countries and provides medical needs of people living with a serious chronic disease into innovative medicines and delivery systems.
Steve Benz is the Corporate Vice President Legal and General Counsel since August 2022.
Published by: www.lawyer-monthly.com
